Sutherland, AE;
Presland, M;
Harrop, E;
Carey, M;
Miller, M;
Wong, ICKC;
(2020)
Orodispersible and transmucosal alternative medications for symptom control in adults.
BMJ Supportive & Palliative Care
10.1136/bmjspcare-2020-002784.
(In press).
Preview |
Text
Wong_BMJ SPcare Orodispersible and Transmucosal Alternative Medications For Symptom Control in Adults.pdf - Accepted Version Download (431kB) | Preview |
Abstract
BACKGROUND: Paediatric palliative care makes frequent use of orodispersible and transmucosal drug delivery routes. The limited published experience of this practice suggests that it enables the delivery of needle-free symptom relief, with the potential to train family carers to administer anticipatory medications without reliance on trained health professionals. AIMS: To identify orodispersible and potential transmucosal alternatives that may be used in adults in the event of a patient having no oral or intravenous route and no access to subcutaneous injections. METHODS: The author panel identified medications through review of multiple drug formularies, review of the published evidence and their experience. Where possible, licensed alternatives were identified and any 'off label' or unlicensed medications clearly highlighted. RESULTS: A list of 27 medications is provided, which could be used either via the orodispersible or transmucosal alternative route for healthcare professionals delivering end of life care to consider when the licensed alternative routes are unavailable. All users of this guide are encouraged to use their professional judgement whenever selecting a medication for a patient, recognising that this review is neither a guideline nor a systematic review, and taking account of licensing considerations, adverse effects, potential unpredictability of time to effect and contraindications. CONCLUSION: Should it be necessary to use these orodispersible or transmucosal alternatives then any experience gained should be reported in the literature. Combined with further research, this experience offers the possibility of reducing injection frequency and inherent delays in medication administration, particularly in the community setting during the COVID-19 pandemic.
Archive Staff Only
 |
View Item |
